These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35463194)

  • 61. Myocardial fibrosis progression on cardiac magnetic resonance in hypertrophic cardiomyopathy.
    Choi HM; Kim KH; Lee JM; Yoon YE; Lee SP; Park EA; Lee W; Kim YJ; Cho GY; Sohn DW; Kim HK
    Heart; 2015 Jun; 101(11):870-6. PubMed ID: 25897040
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prolonged mHealth-Based Arrhythmia Monitoring in Patients With Hypertrophic Cardiomyopathy (HCM-PATCH): Protocol for a Single-Center Cohort Study.
    Schulze Lammers S; Lawrenz T; Lawin D; Hoyer A; Stellbrink C; Albrecht UV
    JMIR Res Protoc; 2023 Dec; 12():e52035. PubMed ID: 38157231
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Hypertrophic Cardiomyopathy-Related Sudden Cardiac Death in Young People in Ontario.
    Weissler-Snir A; Allan K; Cunningham K; Connelly KA; Lee DS; Spears DA; Rakowski H; Dorian P
    Circulation; 2019 Nov; 140(21):1706-1716. PubMed ID: 31630535
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Natural language processing of implantable cardioverter-defibrillator reports in hypertrophic cardiomyopathy: A paradigm for longitudinal device follow-up.
    Siontis KC; Bhopalwala H; Dewaswala N; Scott CG; Noseworthy PA; Geske JB; Ommen SR; Nishimura RA; Ackerman MJ; Friedman PA; Arruda-Olson AM
    Cardiovasc Digit Health J; 2021 Oct; 2(5):264-269. PubMed ID: 34734207
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Myocardial tissue characterization by gadolinium-enhanced cardiac magnetic resonance imaging for risk stratification of adverse events in hypertrophic cardiomyopathy.
    Raiker N; Vullaganti S; Collins JD; Allen BD; Choudhury L
    Int J Cardiovasc Imaging; 2020 Jun; 36(6):1147-1156. PubMed ID: 32166506
    [TBL] [Abstract][Full Text] [Related]  

  • 66. High T2-weighted signal intensity for risk prediction of sudden cardiac death in hypertrophic cardiomyopathy.
    Gommans DHF; Cramer GE; Bakker J; Dieker HJ; Michels M; Fouraux MA; Marcelis CLM; Verheugt FWA; Timmermans J; Brouwer MA; Kofflard MJM
    Int J Cardiovasc Imaging; 2018 Jan; 34(1):113-120. PubMed ID: 29063221
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Impact of cardiac magnetic resonance on the diagnosis of hypertrophic cardiomyopathy - a 10-year experience with over 1000 patients.
    Śpiewak M; Kłopotowski M; Ojrzyńska N; Petryka-Mazurkiewicz J; Miłosz-Wieczorek B; Mazurkiewicz Ł; Grzybowski J; Bilińska Z; Witkowski A; Marczak M
    Eur Radiol; 2021 Mar; 31(3):1194-1205. PubMed ID: 32876838
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Advanced imaging for risk stratification of sudden death in hypertrophic cardiomyopathy.
    Ramchand J; Fava AM; Chetrit M; Desai MY
    Heart; 2020 Jun; 106(11):793-801. PubMed ID: 31949025
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Entropy of left ventricular late gadolinium enhancement and its prognostic value in hypertrophic cardiomyopathy a new CMR assessment method.
    Zhao X; Jin F; Wang J; Zhao X; Wang L; Wei H
    Int J Cardiol; 2023 Feb; 373():134-141. PubMed ID: 36395920
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Comparison on CMR characteristics and clinical prognosis between hypertrophic cardiomyopathy patients with and without left ventricular apical aneurysms].
    Song YY; Lu MJ; Li L; Cui C; Cheng HB; Chen XY; Yin G; Zhao SH
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Mar; 47(3):204-208. PubMed ID: 30897879
    [No Abstract]   [Full Text] [Related]  

  • 71. The Clinical Prognosis of Presence and Location of Late Gadolinium Enhancement by Cardiac Magnetic Resonance Imaging in Patients with Hypertrophic Cardiomyopathy: a Single-Center Cohort Study.
    Li X; Lai L; Luo R; Yang H; Ma H; Yang Z; Zhao S; Su W; Hua W
    J Cardiovasc Transl Res; 2021 Oct; 14(5):1001-1016. PubMed ID: 33629154
    [TBL] [Abstract][Full Text] [Related]  

  • 72. CMR feature tracking strain patterns and their association with circulating cardiac biomarkers in patients with hypertrophic cardiomyopathy.
    Cavus E; Muellerleile K; Schellert S; Schneider J; Tahir E; Chevalier C; Jahnke C; Radunski UK; Adam G; Kirchhof P; Blankenberg S; Lund GK; Avanesov M; Patten M
    Clin Res Cardiol; 2021 Nov; 110(11):1757-1769. PubMed ID: 33779809
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Maximal Wall Thickness Measurement in Hypertrophic Cardiomyopathy: Biomarker Variability and its Impact on Clinical Care.
    Captur G; Manisty CH; Raman B; Marchi A; Wong TC; Ariga R; Bhuva A; Ormondroyd E; Lobascio I; Camaioni C; Loizos S; Bonsu-Ofori J; Turer A; Zaha VG; Augutsto JB; Davies RH; Taylor AJ; Nasis A; Al-Mallah MH; Valentin S; Perez de Arenaza D; Patel V; Westwood M; Petersen SE; Li C; Tang L; Nakamori S; Nezafat R; Kwong RY; Ho CY; Fraser AG; Watkins H; Elliott PM; Neubauer S; Lloyd G; Olivotto I; Nihoyannopoulos P; Moon JC
    JACC Cardiovasc Imaging; 2021 Nov; 14(11):2123-2134. PubMed ID: 34147459
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Evaluation of Hypertrophic Cardiomyopathy: Newer Echo and MRI Approaches.
    Habib M; Hoss S; Rakowski H
    Curr Cardiol Rep; 2019 Jun; 21(8):75. PubMed ID: 31243594
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The role of cardiac magnetic resonance in hypertrophic cardiomyopathy.
    Duarte S; Bogaert J
    Rev Port Cardiol; 2010 Jan; 29(1):79-93. PubMed ID: 20391901
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Novel insights into diminished cardiac reserve in non-obstructive hypertrophic cardiomyopathy from four-dimensional flow cardiac magnetic resonance component analysis.
    Ashkir Z; Johnson S; Lewandowski AJ; Hess A; Wicks E; Mahmod M; Myerson S; Ebbers T; Watkins H; Neubauer S; Carlhäll CJ; Raman B
    Eur Heart J Cardiovasc Imaging; 2023 Aug; 24(9):1192-1200. PubMed ID: 37114738
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy.
    Chan RH; Maron BJ; Olivotto I; Pencina MJ; Assenza GE; Haas T; Lesser JR; Gruner C; Crean AM; Rakowski H; Udelson JE; Rowin E; Lombardi M; Cecchi F; Tomberli B; Spirito P; Formisano F; Biagini E; Rapezzi C; De Cecco CN; Autore C; Cook EF; Hong SN; Gibson CM; Manning WJ; Appelbaum E; Maron MS
    Circulation; 2014 Aug; 130(6):484-95. PubMed ID: 25092278
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The Role of Cardiovascular Magnetic Resonance Imaging in the Evaluation of Hypertrophic Cardiomyopathy.
    Sivalokanathan S
    Diagnostics (Basel); 2022 Jan; 12(2):. PubMed ID: 35204405
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Machine Learning for Predicting Heart Failure Progression in Hypertrophic Cardiomyopathy.
    Fahmy AS; Rowin EJ; Manning WJ; Maron MS; Nezafat R
    Front Cardiovasc Med; 2021; 8():647857. PubMed ID: 34055932
    [No Abstract]   [Full Text] [Related]  

  • 80. The usefulness of sST2 and galectin-3 as novel biomarkers for better risk stratification in hypertrophic cardiomyopathy.
    Gawor M; Śpiewak M; Janas J; Kożuch K; Wróbel A; Mazurkiewicz Ł; Baranowski R; Marczak M; Grzybowski J
    Kardiol Pol; 2017; 75(10):997-1004. PubMed ID: 28612913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.